| 摘要 |
Described is a composition comprising a synergistic combination of a tyrosine kinase inhibitor and a chemical castration agent. The tyrosine kinase inhibitor is selected from a trkA inhibitor, a trkB inhibitor, a trkC inhibitor, or an indolocarbazole. The chemical castration agents include oestrogens; LHRH agonists, e.g., leuprolide acetate (LUPRON®) and goserelin acetate (ZOLADEX®); LHRH antagonists, e.g., ANTIDE® (Ares-Serono) and GANIRELIX® (Akzo Nobel); and antiandrogens, e.g., flutamide and nilutamide. The use of aforementioned tyrosine kinase inhibitors and chemical castration agents in the preparation of a medicament for inhibiting prostrate tumour progression in a mammal is also described. (62) Divided out of 502646
|
